The future of Waldenström’s macroglobulinemia therapy is bright, with various novel combinations currently under investigation. In this video, Jorge Castillo, MD, Dana-Farber Cancer Institute, Boston, MA, delineates what’s on the therapeutic landscape for Waldenström’s. Specifically discussed is the combinatorial use of ibrutinib to achieve deeper responses. For example, ibrutinib is currently being trialed in combination with chemoimmunotherapy, proteasome inhibitors, the CXCR4 inhibitor, EPI-X 4, daratumumab and venetoclax. This interview took place during the 7th World Congress on Controversies in Multiple Myeloma (COMy), 2021.
Jorge Castillo receives research funds and/or honoraria from Abbvie, Beigene, Janssen, Pharmacyclics, Roche, TG Therapeutics